<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03234036</url>
  </required_header>
  <id_info>
    <org_study_id>205820</org_study_id>
    <nct_id>NCT03234036</nct_id>
  </id_info>
  <brief_title>A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir</brief_title>
  <official_title>A Two Part Study to Assess i) the Relative Bioavailability and Food Effect of a Novel Tablet Formulation of Boosted-GSK2838232 Compared to Capsule and ii) the Safety and Pharmacokinetics of Repeated Once-Daily Doses of Non-boosted GSK2838232</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted in two Parts to confirm the acceptability/selection of a tablet
      formulation for future clinical development of GSK2838232. Part 1 of the study will assess
      single ritonavir (RTV)-boosted doses of a new tablet formulation given with food (containing
      approximately 30% fat) against the reference capsule formulation also given with food and
      then will assess the impact of fasted conditions on the tablet performance. In Part 2,
      non-boosted GSK2838232 will be given as once-daily tablet doses for 11 days in a separate
      group of subjects, assuming the tablet performance is considered acceptable from Part 1.
      Approximately 16 healthy subjects will be enrolled to provide at least 12 evaluable subjects
      through the three study periods in Part 1. 10 healthy subjects will be enrolled to provide at
      least 8 evaluable subjects through the single study period in Part 2. The maximum duration of
      study participation will be approximately 9 to 10 weeks for Part 1; and 8 to 9 weeks for Part
      2.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2, 2017</start_date>
  <completion_date type="Actual">November 10, 2017</completion_date>
  <primary_completion_date type="Actual">November 10, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The randomization number will determine the allocation of treatment sequences (ABC or BAC) for Part 1, and of treatment (GSK2838232 without RTV or placebo) for Part 2. Allocation to treatment for Part 1A or Part 1B (with Part 2 being fixed) will be according to a predetermined random order.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Part 1 of the study will be open label and thus not be blinded. Part 2 of the study will be single blinded because of the unavailability of matching placebo tablets. The Principal Investigator and the subject will be completely blinded to specific treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) from time zero (pre-dose) extrapolated to infinite time (AUC [0-inf]) of GSK2838232: Part 1A</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hour post-dose in Period 1 and 2 of Part 1A</time_frame>
    <description>Blood sample will be collected at given time points to study the relative bioavailability of a novel GSK2838232 tablet formulations versus the capsule formulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) of GSK2838232: Part 1A</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hour post-dose in Period 1 and 2 of Part 1A</time_frame>
    <description>Blood sample will be collected at given time points to study the relative bioavailability of a novel GSK2838232 tablet formulations versus the capsule formulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-inf) of GSK2838232: Part 1A and Part 1B</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hour post-dose in Period 1 through 3 of Part 1</time_frame>
    <description>Blood sample will be collected at given time points to study the effect of food on GSK2838232 exposure of the tablet formulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of GSK2838232: Part 1A and Part 1B</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hour post-dose in Period 1 through 3 of Part 1</time_frame>
    <description>Blood sample will be collected at given time points to study the effect of food on GSK2838232 exposure of the tablet formulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of occurrence of Cmax (Tmax) of GSK2838232: Part 1A and Part 1B</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hour post-dose in Period 1 through 3 of Part 1</time_frame>
    <description>Blood sample will be collected at given time points to study the effect of food on GSK2838232 exposure of the tablet formulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse events (AEs) and serious AEs (SAEs): Part 2</measure>
    <time_frame>Up to Day 25 in Part 2</time_frame>
    <description>An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment, or associated with liver injury and impaired liver function, will be categorized as SAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of hemoglobin, total protein and albumin: Part 2</measure>
    <time_frame>Up to Day 25 in Part 2</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of hematocrit: Part 2</measure>
    <time_frame>Up to Day 25 in Part 2</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of neutrophils, lymphocytes, monocytes, eosinophils, basophils and platelet count: Part 2</measure>
    <time_frame>Up to Day 25 in Part 2</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of creatinine, total and direct bilirubin: Part 2</measure>
    <time_frame>Up to Day 25 in Part 2</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase: Part 2</measure>
    <time_frame>Up to Day 25 in Part 2</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of blood urea nitrogen (BUN), sodium, potassium, calcium, glucose and triglycerides: Part 2</measure>
    <time_frame>Up to Day 25 in Part 2</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein cholesterol (VLDLc) (calculated) and Non-HDLc (calculated) : Part 2</measure>
    <time_frame>Up to Day 25 in Part 2</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of lipase: Part 2</measure>
    <time_frame>Up to Day 25 in Part 2</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of mean corpuscular hemoglobin (MCH): Part 2</measure>
    <time_frame>Up to Day 25 in Part 2</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of mean corpuscular volume (MCV): Part 2</measure>
    <time_frame>Up to Day 25 in Part 2</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of red blood cell (RBC) count: Part 2</measure>
    <time_frame>Up to Day 25 in Part 2</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with urinalysis dipstick results: Part 2</measure>
    <time_frame>Up to Day 25 in Part 2</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of urine power of hydrogen (pH): Part 2</measure>
    <time_frame>Up to Day 25 in Part 2</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of specific gravity of urine: Part 2</measure>
    <time_frame>Up to Day 25 in Part 2</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of systolic blood pressure (SBP) and diastolic blood pressure (DBP): Part 2</measure>
    <time_frame>Up to Day 25 in Part 2</time_frame>
    <description>Blood pressure (BP) will be measured in supine position after 10 minutes rest. BP will be taken in triplicate (taken 5 minutes apart) at pre-dose on Days 1 and 11 and singular at all other measurement time points in Part 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of heart rate (HR): Part 2</measure>
    <time_frame>Up to Day 25 in Part 2</time_frame>
    <description>HR will be measured in supine position after 10 minutes rest. HR will be taken in triplicate (taken 5 minutes apart) at pre-dose on Days 1 and 11 and singular at all other measurement time points in Part 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of electrocardiogram (ECG) parameters: Part 2</measure>
    <time_frame>Up to Day 25 in Part 2</time_frame>
    <description>Triplicate 12-lead ECGs will be obtained at least 5 minutes apart in the supine position after 10 minutes of rest at pre-dose on Days 1 and 11 and singular at all other measurement time points in Part 2. It will be recorded using an ECG machine that automatically calculates the HR and measures PR, QRS, QT and QT duration corrected for HR by Fridericia's formula (QTcF) intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from pre-dose to the end of the dosing interval at steady state (AUC [0-tau]) of GSK2838232 after single dose on Day 1 in Part 2</measure>
    <time_frame>Day 1: pre-dose and 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hour post-dose (prior to Day 2 dose) in Part 2</time_frame>
    <description>Blood sample will be collected at given time points to study the pharmacokinetics (PK) of GSK2838232 administered as non-boosted dose of a tablet formulation on Day 1in Part 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of GSK2838232 after single dose on Day 1 in Part 2</measure>
    <time_frame>Day 1: pre-dose and 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hour post-dose (prior to Day 2 dose) in Part 2</time_frame>
    <description>Blood sample will be collected at given time points to study the PK of GSK2838232 administered as non-boosted dose of a tablet formulation on Day 1in Part 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough concentration (Ctau) of GSK2838232 after single dose on Day 1 in Part 2</measure>
    <time_frame>Day 1: pre-dose and 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hour post-dose (prior to Day 2 dose) in Part 2</time_frame>
    <description>Blood sample will be collected at given time points to study the PK of GSK2838232 administered as non-boosted dose of a tablet formulation on Day 1in Part 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of GSK2838232 after single dose on Day 1 in Part 2</measure>
    <time_frame>Day 1: pre-dose and 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hour post-dose (prior to Day 2 dose) in Part 2</time_frame>
    <description>Blood sample will be collected at given time points to study the PK of GSK2838232 administered as non-boosted dose of a tablet formulation on Day 1in Part 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lag-time (Tlag) of GSK2838232 after single dose on Day 1 in Part 2</measure>
    <time_frame>Day 1: pre-dose and 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hour post-dose (prior to Day 2 dose) in Part 2</time_frame>
    <description>Tlag is the time delay between drug administration and first observed concentration above limit of quantification (LOQ) in plasma. Blood sample will be collected at given time points to study the PK of GSK2838232 administered as non-boosted dose of a tablet formulation on Day 1in Part 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-tau) of GSK2838232 after repeat dose in Part 2</measure>
    <time_frame>Days 2 to 10: pre-dose; Day 11: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hour post-dose in Part 2</time_frame>
    <description>Blood sample will be collected at given time points to study the PK of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days in Part 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-inf) of GSK2838232 after repeat dose in Part 2</measure>
    <time_frame>Days 2 to 10: pre-dose; Day 11: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hour post-dose in Part 2</time_frame>
    <description>Blood sample will be collected at given time points to study the PK of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days in Part 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of GSK2838232 after repeat dose in Part 2</measure>
    <time_frame>Days 2 to 10: pre-dose; Day 11: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hour post-dose in Part 2</time_frame>
    <description>Blood sample will be collected at given time points to study the PK of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days in Part 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ctau of GSK2838232 after repeat dose in Part 2</measure>
    <time_frame>Days 2 to 10: pre-dose; Day 11: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hour post-dose in Part 2</time_frame>
    <description>Blood sample will be collected at given time points to study the PK of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days in Part 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of GSK2838232 after repeat dose in Part 2</measure>
    <time_frame>Days 2 to 10: pre-dose; Day 11: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hour post-dose in Part 2</time_frame>
    <description>Blood sample will be collected at given time points to study the PK of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days in Part 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal phase half-life (T1/2) of GSK2838232 after repeat dose in Part 2</measure>
    <time_frame>Days 2 to 10: pre-dose; Day 11: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hour post-dose in Part 2</time_frame>
    <description>Blood sample will be collected at given time points to study the PK of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days in Part 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The time of the last measurable concentration (Tlast) of GSK2838232 after repeat dose in Part 2</measure>
    <time_frame>Days 2 to 10: pre-dose; Day 11: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hour post-dose in Part 2</time_frame>
    <description>Blood sample will be collected at given time points to study the PK of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation for 11 days in Part 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with AEs and SAEs: Part 1</measure>
    <time_frame>Up to Day 66</time_frame>
    <description>An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment, or associated with liver injury and impaired liver function, will be categorized as SAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of hemoglobin, total protein and albumin: Part 1</measure>
    <time_frame>Up to Day 66</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety and tolerability of GSK2838232 following single dose administration as tablets or capsules, with RTV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of hematocrit: Part 1</measure>
    <time_frame>Up to Day 66</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety and tolerability of GSK2838232 following single dose administration as tablets or capsules, with RTV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of neutrophils, lymphocytes, monocytes, eosinophils, basophils and platelet count: Part 1</measure>
    <time_frame>Up to Day 66</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety and tolerability of GSK2838232 following single dose administration as tablets or capsules, with RTV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of creatinine, total and direct bilirubin: Part 1</measure>
    <time_frame>Up to Day 66</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety and tolerability of GSK2838232 following single dose administration as tablets or capsules, with RTV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of AST, alanine aminotransferase ALT and alkaline phosphatase: Part 1</measure>
    <time_frame>Up to Day 66</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety and tolerability of GSK2838232 following single dose administration as tablets or capsules, with RTV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of BUN, sodium, potassium, calcium, glucose and triglycerides: Part 1</measure>
    <time_frame>Up to Day 66</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety and tolerability of GSK2838232 following single dose administration as tablets or capsules, with RTV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of total cholesterol, HDL, LDL, VLDLc (calculated) and Non-HDLc (calculated) : Part 1</measure>
    <time_frame>Up to Day 66</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety and tolerability of GSK2838232 following single dose administration as tablets or capsules, with RTV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of lipase: Part 1</measure>
    <time_frame>Up to Day 66</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety and tolerability of GSK2838232 following single dose administration as tablets or capsules, with RTV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of MCH: Part 1</measure>
    <time_frame>Up to Day 66</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety and tolerability of GSK2838232 following single dose administration as tablets or capsules, with RTV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of MCV: Part 1</measure>
    <time_frame>Up to Day 66</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety and tolerability of GSK2838232 following single dose administration as tablets or capsules, with RTV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of RBC count: Part 1</measure>
    <time_frame>Up to Day 66</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety and tolerability of GSK2838232 following single dose administration as tablets or capsules, with RTV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with urinalysis dipstick results: Part 1</measure>
    <time_frame>Up to Day 66</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety and tolerability of GSK2838232 following single dose administration as tablets or capsules, with RTV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of urine pH: Part 1</measure>
    <time_frame>Up to Day 66</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety and tolerability of GSK2838232 following single dose administration as tablets or capsules, with RTV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of specific gravity of urine: Part 1</measure>
    <time_frame>Up to Day 66</time_frame>
    <description>Clinical laboratory parameters will be evaluated to investigate the safety and tolerability of GSK2838232 following single dose administration as tablets or capsules, with RTV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of SBP and DBP: Part 1</measure>
    <time_frame>Up to Day 66</time_frame>
    <description>BP will be measured in supine position after 10 minutes rest. BP will be taken in triplicate (taken 5 minutes apart) at pre-dose on Day 1 and singular at all other measurement time points in Part 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of HR: Part 1</measure>
    <time_frame>Up to Day 66</time_frame>
    <description>HR will be measured in supine position after 10 minutes rest. HR will be taken in triplicate (taken 5 minutes apart) at pre-dose on Day 1 and singular at all other measurement time points in Part 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes over time from pre-dose values of ECG parameters: Part 1</measure>
    <time_frame>Up to Day 66</time_frame>
    <description>Triplicate 12-lead ECGs will be obtained at least 5 minutes apart in the supine position after 10 minutes of rest at pre-dose on Day 1 and singular at all other measurement time points in Part 1. It will be recorded using an ECG machine that automatically calculates the HR and measures PR, QRS, QT and QTcF intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tlag of GSK2838232: Part 1A and Part 1B</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hour post-dose in Period 1 through 3 of Part 1</time_frame>
    <description>Tlag is the time delay between drug administration and first observed concentration above limit of quantification (LOQ) in plasma. Blood sample will be collected at given time points to study the Pharmacokinetics (PK) of GSK2838232 after administration of a novel tablet formulation and capsule formulation with food, and the tablet formulation given without food.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of GSK2838232: Part 1A and Part 1B</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hour post-dose in Period 1 through 3 of Part 1</time_frame>
    <description>Blood sample will be collected at given time points to study the PK of GSK2838232 after administration of a novel tablet formulation and capsule formulation with food, and the tablet formulation given without food.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tlast of GSK2838232: Part 1A and Part 1B</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hour post-dose in Period 1 through 3 of Part 1</time_frame>
    <description>Blood sample will be collected at given time points to study the PK of GSK2838232 after administration of a novel tablet formulation and capsule formulation with food, and the tablet formulation given without food.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma drug concentration at 24 hour after administration of GSK2838232: Part 1A and Part 1B</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hour post-dose in Period 1 through 3 of Part 1</time_frame>
    <description>Blood sample will be collected at given time points to study the PK of GSK2838232 after administration of a novel tablet formulation and capsule formulation with food, and the tablet formulation given without food.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from zero up to a definite time t (AUC [0-t]) of GSK2838232: Part 1</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hour post-dose in Period 1 through 3 of Part 1</time_frame>
    <description>Blood sample will be collected at given time points to study the PK of GSK2838232 after administration of a novel tablet formulation and capsule formulation with food, and the tablet formulation given without food.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose concentrations of GSK2838232on Days 2 to 11 in Part 2</measure>
    <time_frame>Pre-dose on Days 2 to 11 in Part 2</time_frame>
    <description>Blood sample will be collected at given time points to assess time to steady-state of GSK2838232 when administered as non-boosted once-daily doses of a tablet formulation for 11 days in Part 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio calculated from AUC(0-tau) (Ro[AUC{0-tau}]) in Part 2</measure>
    <time_frame>Day 1: pre-dose and 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hour post-dose (prior to Day 2 dose) in Part 2; Day 11: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hour post-dose in Part 2</time_frame>
    <description>The extent of accumulation of GSK2838232 will be evaluated by comparing AUC(0-tau) between Day 11 and Day 1 after administration of non-boosted once-daily doses of a tablet formulation in Part-2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio calculated from Cmax (Ro[Cmax]) in Part 2</measure>
    <time_frame>Day 1: pre-dose and 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hour post-dose (prior to Day 2 dose) in Part 2; Day 11: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hour post-dose in Part 2</time_frame>
    <description>The extent of accumulation of GSK2838232 will be evaluated by comparing Cmax between Day 11 and Day 1 after administration of non-boosted once-daily doses of a tablet formulation in Part-2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio calculated from Ctau (Ro[Ctau]) in Part 2</measure>
    <time_frame>Day 1: pre-dose and 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hour post-dose (prior to Day 2 dose) in Part 2; Day 11: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hour post-dose in Part 2</time_frame>
    <description>The extent of accumulation of GSK2838232 will be evaluated by comparing Ctau between Day 11 and Day 1 after administration of non-boosted once-daily doses of a tablet formulation in Part-2.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Treatment sequence ABC: Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 1 in Part 1A.
A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 2 in Part 1A.
Both these treatments in Part 1A will be administered with RTV in fed state with a washout of 10 days.
A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.
There will be a wash out of 15 days between Part 1A and Part 1B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence BAC: Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 1 in Part 1A.
A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 2 in Part 1A.
A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.
There will be a wash out of 15 days between Part 1A and Part 1B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2838232 tablet without RTV: Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 2, subjects will receive non-RTV boosted GSK2838232 500 mg, given as single daily doses for 11 days. The dose will not exceed 500 mg (as 5 x 100 mg tablets) once daily (QD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo without RTV: Part 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In Part 2, subjects will receive a Placebo given as single daily doses for 11 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2838232 100 mg tablet</intervention_name>
    <description>It is a white to slightly colored tablet. It will be supplied as prefilled tablets in bulk for dispensing to subjects at the site according to the treatment code.</description>
    <arm_group_label>Treatment sequence BAC: Part 1</arm_group_label>
    <arm_group_label>GSK2838232 tablet without RTV: Part 2</arm_group_label>
    <arm_group_label>Treatment sequence ABC: Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2838232 50 mg capsule</intervention_name>
    <description>It is a pink unmarked capsule. It will be supplied as prefilled capsules in bulk for dispensing to subjects at the site according to the treatment code.</description>
    <arm_group_label>Treatment sequence BAC: Part 1</arm_group_label>
    <arm_group_label>Treatment sequence ABC: Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir 100 mg tablets</intervention_name>
    <description>It is a white film-coated ovaloid tablets.</description>
    <arm_group_label>Treatment sequence BAC: Part 1</arm_group_label>
    <arm_group_label>Treatment sequence ABC: Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for GSK2838232 tablets</intervention_name>
    <description>It is a white to slightly colored tablet. The placebo tablets supplied will not be identical to GSK2838232 tablets. It will be administered by site staff via an opaque card or paper tube.</description>
    <arm_group_label>Placebo without RTV: Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 55 years of age inclusive, at the time of signing the informed consent.

          -  Healthy as determined by the Investigator or medically qualified designee based on a
             medical evaluation including medical history, physical examination, laboratory tests
             and cardiac monitoring.

          -  A subject with a clinical abnormality or laboratory parameter(s) which is/are not
             specifically listed in the inclusion or exclusion criteria, and outside the reference
             range for the population being studied, may be included only if the Investigator in
             consultation with the medical monitor, if required, agree and document that the
             finding is unlikely to introduce additional risk factors and will not interfere with
             the study procedures.

          -  A creatinine clearance (CLcr) &gt; 80 milliliter per minute (mL/min) as determined by
             Cockcroft-Gault equation: CLcr = (140 minus age) multiplied by weight divided by (72
             multiplied by serum creatinine) (times 0.85 if female) where age is in years, weight
             in kilogram (kg), and serum creatinine is in units of milligram per deciliter (mg/dL).

          -  Body weight &gt;=50.0 kg (110 pounds [lbs.]) for men and &gt;=45.0 kg (99 lbs) for women and
             body mass index (BMI) within the range 18.5 to 31.0 kg/meter (m)^2 (inclusive).

          -  Males or females.

          -  A female subject is eligible to participate if she is not pregnant (as confirmed by a
             negative serum human chorionic gonadotrophin [hCG] test), not lactating, and of
             non-reproductive potential which is defined as:

        Reproductive potential:

        There is no definitive drug-drug interaction (DDI) information with GSK2838232 and an
        interaction with oral contraceptives is possible, so other (barrier, inter-uterine device
        etc.) methods of contraception will be required. Females of reproductive potential may only
        be enrolled if they are using two forms of complementary contraception, which must include
        at least one barrier method. They will be counseled on safer sex practices. Fertile
        females, who have an established, long-term lifestyle of sexual abstinence, or only same
        sex partners, require no other means of birth control.

        Non-reproductive potential:

          -  Pre-menopausal females with one of the following: Documented tubal ligation;
             documented hysteroscopic tubal occlusion procedure with follow-up confirmation of
             bilateral tubal occlusion; hysterectomy; documented Bilateral Oophorectomy.

          -  Postmenopausal defined as 12 months of spontaneous amenorrhea in questionable cases a
             blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels
             consistent with menopause. Females on hormone replacement therapy (HRT) must
             discontinue HRT to allow confirmation of post-menopausal status prior to study
             enrolment.

               -  Male subjects with female partners of child bearing potential must comply with
                  the following contraception requirements from the time of first dose of study
                  medication until one week after the last dose of study medication.

          -  Vasectomy with documentation of azoospermia.

          -  Male condom plus partner use of one of the contraceptive options below: Contraceptive
             subdermal implant with a &lt;1 percent rate of failure per year; intrauterine device or
             intrauterine system with a &lt;1 percent rate of failure per year; oral contraceptive,
             either combined or progestogen alone or injectable progestogen; contraceptive vaginal
             ring; percutaneous contraceptive patches.

               -  Capable of giving signed informed consent.

        Exclusion Criteria:

          -  ALT &gt;1.5 times upper limit of normal (ULN)

          -  Bilirubin &gt;1.5 times ULN (isolated bilirubin &gt;1.5 times ULN is acceptable if bilirubin
             is fractionated and direct bilirubin &lt;35 percent).

          -  Current or chronic history of liver disease, or known hepatic or biliary
             abnormalities.

          -  Subjects who have asthma or a history of asthma.

          -  Medical history of cardiac arrhythmias or cardiac disease or a family or personal
             history of long QT syndrome.

          -  Unable to refrain from the use of prescription or non-prescription drugs, including
             vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or
             14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is
             longer) prior to the first dose of study medication, unless in the opinion of the
             Investigator and GlaxoSmithKline medical monitor, the medication will not interfere
             with the study procedures or compromise participant safety.

          -  History of regular alcohol consumption (within 6 months prior to screening or unable
             to refrain from alcohol use from 5 days prior to admission through the last blood
             sample collected) defined as:

             â€¢ For United States sites: an average weekly intake of &gt;14 drinks for males or &gt;7
             drinks for females. One drink is equivalent to 12 gram of alcohol: 12 ounces (360 mL)
             of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled
             spirits.

          -  Regular use of tobacco- or nicotine- containing products within 6 months prior to
             screening. Unable to refrain from smoking from the Screening Visit through the last
             blood sample collected. As confirmed by a urine cotinine test.

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the investigator or medical
             monitor, contraindicates their participation.

          -  Presence of hepatitis B surface antigen (HBsAg), or positive hepatitis C virus (HCV)
             test result at screening or within 3 months prior to first dose of study treatment.

          -  Screening or Baseline cardiac troponin I greater than the 99 percent cutoff (&gt;0.045
             nanogram [ng]/mL by the Dimension Vista cTnI assay) for a given assay.

          -  A positive pre-study drug/alcohol screen.

          -  A positive test for human immunodeficiency virus (HIV) antibody.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within 56 days.

          -  The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day.

          -  Exclusion Criteria for 24-hour Screening Holter:

               -  Any symptomatic arrhythmia (except isolated extra systoles).

               -  Sustained cardiac arrhythmias (such as atrial fibrillation or flutter,
                  supraventricular tachycardia (&gt;= 10 consecutive beats), complete heart block).

               -  Non-sustained or sustained ventricular tachycardia (defined as &gt;=3 consecutive
                  ventricular ectopic beats).

               -  Any conduction abnormality (including but not specific to left or right
                  incomplete or complete bundle branch block, atrioventricular (AV) block [2nd
                  degree or higher], Wolff Parkinson White (WPW) syndrome etc.).

               -  Sinus Pauses &gt;3 seconds.

               -  300 or more supraventricular ectopic beats in 24 hours.

               -  250 or more ventricular ectopic beats in 24 hours.

          -  Any clinically significant abnormal echocardiogram finding.

          -  Exclusion criteria for screening ECG (a single repeat is allowed for eligibility
             determination):

               -  Heart rate &lt;45 or &gt;100 beats per minute (bpm) for males; &lt;50 or &gt;100 bpm for
                  females

               -  PR interval &lt;120 or &gt;220 milliseconds (msec)

               -  QRS duration &lt;70 or &gt;120 msec

               -  QTc interval (Fridericia's) &gt;450 msec

               -  Evidence of previous myocardial infarction (does not include ST segment changes
                  associated with re-polarization).

               -  Any conduction abnormality (including but not specific to left or right complete
                  bundle branch block, AV block [2nd degree or higher], WPW syndrome).

               -  Sinus Pauses &gt;3 seconds.

               -  Any significant arrhythmia which, in the opinion of the Investigator or GSK
                  medical monitor, will interfere with the safety for the individual subject.

               -  Non-sustained or sustained ventricular tachycardia (&gt;=3 consecutive ventricular
                  ectopic beats).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2017</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK2838232</keyword>
  <keyword>safety</keyword>
  <keyword>food effect</keyword>
  <keyword>capsule</keyword>
  <keyword>healthy</keyword>
  <keyword>PK</keyword>
  <keyword>tablet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

